Why the study?
In older adults with AF treated with minimal antiplatelet/anticoagulant therapy after MI or PCI due to bleeding concerns, the risk of recurrent MI or PCI prompting extended therapy is unknown.
What is the long-term incidence of recurrent MI or PCI and the utilization of combined antithrombotic therapy in older adults with AF after acute MI?
What is the long-term incidence of recurrent MI or PCI and the utilization of combined antithrombotic therapy in older adults with AF after acute MI?
Older adults with AF and MI have a high long-term risk of recurrent ischemic events requiring extended antithrombotic therapy, but are frequently undertreated with combined oral anticoagulation and P2Y12 inhibitors.
Recurrent MI/PCI in ~25% over 7 years may extend antithrombotic needs; leaves open optimal duration strategies for randomized trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: